GlassScriptPhysician profile
Gloria Margison
NPI 1134231285
$12,622.82
in general payments reported to CMS, 2019-2025
37 companies · $2,176 in 2025
The $2,176 reported for 2025 was more than what 95% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,160 · 2022: $2,785 · 2023: $2,170 · 2024: $2,333 · 2025: $2,176.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,674 · Education: $4.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,674.26 |
| Education | $4.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,467.17 | 2021-2025 | Farxiga, Breztri, Fasenra |
| Lilly USA, LLC | $1,294.30 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $1,120.05 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $864.37 | 2022-2025 | |
| Glaxosmithkline, LLC. | $610.73 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $563.93 | 2021-2025 | Jardiance |
| Novo Nordisk INC | $541.97 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Insulet Corporation | $435.03 | 2021-2025 | Omnipod |
| Merck Sharp & Dohme LLC | $416.93 | 2021-2025 | Verquvo, Belsomra, Steglatro |
| Corcept Therapeutics | $404.34 | 2023-2025 | Korlym |
| Biohaven Pharmaceuticals, INC. | $312.49 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $287.23 | 2021-2025 | Xifaxan, Trulance |
| Astellas Pharma US INC | $280.73 | 2021-2025 | Veozah, Myrbetriq |
| Sanofi-Aventis U.S. LLC | $237.55 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $203.91 | 2021-2025 | Gvoke Hypopen |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $184.51 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $144.59 | 2021-2025 | |
| Amgen INC. | $143.20 | 2023-2025 | Tezspire, Otezla, Repatha |
| Verona Pharma, INC. | $137.50 | 2025 | Ohtuvayre |
| Sunovion Pharmaceuticals INC. | $136.49 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $111.60 | 2024-2025 | Caplyta |
| Ultragenyx Pharmaceutical INC. | $93.88 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $84.49 | 2021-2023 | Trintellix |
| Phathom Pharmaceuticals, INC. | $81.31 | 2023-2025 | Voquezna |
| Exact Sciences Corporation | $79.87 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Otsuka America Pharmaceutical, INC. | $52.32 | 2022-2023 | Rexulti, Abilify Maintena |
| Biohaven Pharmaceutical Holding Company LTD. | $52.09 | 2022 | |
| Vanda Pharmaceuticals INC. | $51.96 | 2024 | Fanapt, Hetlioz |
| Dexcom, INC. | $50.42 | 2024 | Dexcom G6 Transmitter |
| Eisai INC. | $48.72 | 2021 | |
| Mylan Specialty L.P. | $38.35 | 2024 | Yupelri |
| Axsome Therapeutics, INC. | $19.65 | 2025 | Auvelity |
| Sumitomo Pharma America, INC. | $18.12 | 2024 | Gemtesa |
| Abbott Laboratories | $17.17 | 2023 | Freestyle Libre 2 |
| Ascensia Diabetes Care US INC. | $14.13 | 2023 | |
| Cequr Corporation | $13.02 | 2025 | Cequr Simplicity |
| Genentech USA, INC. | $8.70 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gloria Margison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.